Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

PHARMAC, Novartis reach agreement on Glivec


PHARMAC, Novartis reach provisional agreement on Glivec

PHARMAC has reached a provisional agreement with Novartis to fund the cancer drug Glivec for a wide group of New Zealanders.

PHARMAC is asking for submissions on its funding proposal, which involves a number of products and is subject to the outcome of consultation and final approval by the PHARMAC Board.

Features of the proposal include:

Funding for all patients with interferon-intolerant chronic phase chronic myeloid leukaemia (CML), and for CML patients in accelerated and blast crisis phases (about 90 people) when approved by Medsafe, funding for Glivec as first line therapy for all CML patients (about 85 further people) funding for all patients with unresectable and/or metastatic gastro-intestinal stromal tumours (GIST) (about 30 people)

“Negotiations on Glivec have been a high priority for PHARMAC and we have been working to reach an agreement as quickly as possible,” says PHARMAC Chief Executive Wayne McNee.

“This provisional agreement is the result of a lot of hard work by staff at both PHARMAC and Novartis.”

“Our negotiations with Novartis have enabled us to reach conditional agreement on a proposal to fund Glivec for all those patients for whom it is currently approved in New Zealand. In addition, PHARMAC is proposing to fund Glivec as a first line therapy for CML patients in chronic phase, if the drug is approved for this by Medsafe.”

“We are pleased to have reached this stage and we now want to hear the views of clinicians and the wider public before making a decision.”

PHARMAC will be considering all responses before taking a recommendation to the PHARMAC Board in October. The proposal includes 11 different products used in both community and hospital settings and involves both rebates and price reductions.

If approved by the PHARMAC Board, Glivec would be available fully funded from 1 December 2002.

PHARMAC is also proposing to implement a recommendation of the Cancer Treatments sub-committee of PTAC that treatment with Glivec can continue until the prescribing specialist decides to stop it.

Details of the proposal are available on the PHARMAC website, www.pharmac.govt.nz.

The deadline for consultation to be received by PHARMAC is Friday 18 October.


© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Media Mega Merger: StuffMe Hearing Argues Over Moveable Feast

New Zealand's two largest news publishers are appealing against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Elsewhere:


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>

ALSO:


Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>

ALSO:

Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>